A simple new model for estimating the screening performance (false positive and false negative rates) of a given test for a specific sample population is presented. The model is shown to give good results on a test population, and is used to estimate the performance on a sampled population. Using the model developed in conjunction with regulatory requirements and the relative costs of the confirmatory and screening tests allows evaluation of the screening test's utility in terms of cost savings. Testers can use the methods developed to estimate the utility of a screening program using available screening tests with their own sample populations.
Introduction
Prior to the 1970's, polychlorinated biphenyls (PCBs) were produced and used extensively as heat-conducting insulating media in electrical equipment, such as transformers and condensers. Since then, the production and new use of PCBs has been discontinued in most of the world as recognition of their toxicity has increased. 1, 2 As of 2013, 179 countries are party to the Stockholm Convention on Persistent Organic Pollutants, which commits them to phase out the use of PCBs completely by 2025 and bring remaining PCBs under environmentally sound waste management by 2028. 3 Electrical transformers have long service lives, and many transformers containing PCBs are believed to still be in service. In Japan, the government has set a maximum residue limit (MRL) of 0.5 mg/kg (for comparison, Korea is 2 mg/kg, and the U.S. is 50 mg/kg) for total PCBs in transformer oil. The Japanese government also mandates that every transformer removed from service must be tested for the presence of PCBs prior to disposal. The reference method for the measurement of PCBs in transformer oil is gas chromatography followed by electron capture detection (GC/ECD). 4 This method is relatively expensive, and often requires several days for the measurement. Owners of large numbers of transformers wish to reduce the cost and time needed to perform testing while still meeting or exceeding the regulatory requirements. For this reason, there is interest in faster and less expensive screening tests in order to reduce the number of confirmatory tests required.
Our laboratories have been developing immunoassays to meet this need for several years. We have previously reported a pretreatment method to extract PCBs from transformer oil 5 and the development of immunoassay systems to measure PCBs easily. [6] [7] [8] We also evaluated the performance (sensitivity and specificity) of the immunoassay systems when used to screen for PCB contamination in Japanese 9,10 and Korean 11 transformer oil.
It is highly desirable to be able to make predictions about the utility of a screening program prior to implementing it. Such analysis has a goal analogous to that of medical researchers selecting the optimum cutoff levels for medical screening tests, 12, 13 but there are also significant differences between medical and environmental screening. In particular, in contrast to medical tests, environmental testing generally has a clear and well-defined level above which samples are contaminated; that is, the positives are determined unambiguously by statute, and are directly tied to the measurement outcomes. In addition, environmental screening tests often must meet a regulatory requirement on their false-negative performance, and thus simplifying the choice of the screening test cutoff level. 14 The goal of an environmental or regulatory screening program is to save money and/or time compared to using the reference method for every sample. Success depends in part on obvious factors, such as the relative cost of the screening test and the regulatory requirements, such as the fraction of screened samples that must be measured using the confirmatory test. Success also depends on the false-positive and false-negative rates as well as the sensitivity and specificity of the screening test; these factors are difficult to predict in advance. Others have recognized the importance of the sample distribution in determining these parameters 15 and the importance of the screening tests reproducibility. 16 However, this report is the first report where a screening tests characterization on known samples is used to estimate the utility of a screening program on an estimated population of samples. The developed model is general, and will allow interested users to estimate the screening utility on other populations and for other tests.
Experimental

Screening utility
The idea of screening is that all samples will be tested with a lower cost screening test, and that only a subset of the samples (usually all of the positives and a fraction of the negatives) will be tested with the higher cost confirmatory test. The actual cost savings that can be realized with this approach depends on five factors:
i) The relative cost of the two kinds of test. In what follows, the CR (cost ratio) is defined as the cost of a single confirmatory test divided by the cost of a single screening test. ii) The fraction of the population that is actually positive.
OR (occurrence ratio) is defined as the fraction of the total sample population that exceeds the MRL. iii) The false positive rate (FP) . This is the fraction of negative samples (PCBs ≤ MRL) that test positive during screening. iv) The false negative rate (FN). This is the fraction of positive samples (PCBs > MRL) that test negative during screening. v) The fraction of confirmatory testing of screening negative
samples. FT (fraction tested) is defined as the fraction of samples that test negative in the screening test that are retested using the confirmatory test. With these factors, the cost save ratio (CS) of screening can be defined as:
In the numerator of Eq. (1), 1 is the (arbitrary) cost of screening all samples. To this is added the cost for confirmatory testing on the fraction of samples that are confirmed, all of those that screen positive, "CR(OR -FN + FP)", and the fraction FT of those that screen negative, "CR*FT*(1 -(OR -FN + FP))". The denominator of Eq. (1), CR is the cost if all samples were measured with the confirmatory test instead of screening. If CS is small (<1), the cost with screening is less than the cost without screening, and adding screening is useful. On the other hand, if CS is large (>1), the method is worse than useless. Eq. (1) can be rearranged as:
In Eq. (2), it is clear that large CR and FN and small OR and FP make CS small (cost is saved by screening). However, a large FN is generally highly undesirable and prohibited by statute. The parameters OR and FT are beyond the control of the end users (OR is a parameter of the sample space, and FT is set by statute). Therefore, the developer of the screening method should pay attention to both CR and FP for small CS.
Equations of false positive and negative rates
FP and FN depend on the interaction between the performance parameters of the screening test and the sample distribution. 15, 16 If the samples are polarized and grouped far from the MRL, then even relatively poor performing screening tests may be able to give excellent performance in terms of FP and FN. On the other hand, if all of the samples are clustered very near to the MRL, then even excellent screening tests may give unsatisfactory values for FN and FP. If the sample distribution, the screening test reproducibility (standard deviation) and the slope and intercept of the screening test results plotted against the true sample values are all known, or can be inferred, it is possible to calculate the FP and FN values for various screening cutoffs in the following manner.
Starting with FN, consider a positive sample. Given the screening cutoff concentration (c), the sample's actual concentration (x), and the screening test's standard deviation (σ), the probability that the screening test will report a result below the cutoff is calculated by integrating the probability distribution of the measurement from negative infinity to the c value (area of diagonal shading in Fig. 1 ). This is conveniently expressed quantitatively using the error function (erf) as
The value of p (0.077 for the example shown in Fig. 1 ) is the probability that this sample (a statutory positive) would be judged to be negative (a false negative) by the screening test. Expanding this concept to calculate the overall false-negative rate (FN), p is calculated for all positive samples, and the summation of all p's is divided by the number of positive samples. Defining three vectors (x, a vector containing the concentration values; σ, a vector of standard deviation at the concentration x; and N, a vector containing the corresponding number of samples at each concentration), an equation for the overall predicted FN can be written as 
The sum is over ps, the collection of all positive samples, because only positive samples can appear as false negatives during screening. Ideally, the average concentrations reported by the screening test would agree perfectly with the actual concentrations, and a plot of the screening values vs. actual values would have a slope of 1 and an intercept of zero. In reality, a bias (slope different than 1 and a non-zero intercept) is expected in the screening results. The standard deviation (σ) is a parameter of the screening test, and represents the reproducibility of the measurement. Generally, this is homoscedastic, 17 a single value, σ, can be used. FN is calculated using Eq. (4), modified so as to include the slope (m), the intercept (b), and the invariant standard deviation (σ): 
The sum is over ns, the collection of all negative samples, because only negative samples can appear as false positives during screening.
Screening example
In order to make use of Eqs. (5) and (6), to estimate the FP and FN rates, it is necessary to first obtain values for the screening test parameters (m, b, and σ). This is most readily accomplished by challenging the screening test with known samples.
In a previous study, 18 103 oil samples were preprocessed according to the SCAS standard method of high-resolution gas chromatography with high-resolution mass spectrometer (HRGC/HRMS), 6 and measured using low-resolution gas chromatography with low-resolution mass spectrometer (LRGC/LRMS) detection, and sent as blind samples to six companies that developed screening tests. Only two of the original six companies (Sumika Analytical Systems (SCAS, Tokyo, Japan) and Kyoto Electronic Manufacturing Inc. (KEM, Kyoto, Japan)), have gone on to produce commercial screening tests available in Japan. Subsequent analysis focuses on these two.
Results and Discussion
Calculation of FN and FP
All 103 samples were measured by each screening test and by LRGC/LRMS for a reference. These values were separated into positives and negatives for a series of cutoff values, and were then further separated into false positives, true positives, false negatives and true negatives by comparing to the LRGC/LRMS measurement of each sample. The false positive and false negative rates (FP and FN) were computed by dividing the false-positive count by the sum of the true negative count plus the false positive count, and the false-negative count by the sum of the true-positive count and the false-negative count. The calculated FP and FN are plotted vs. the cutoff in Fig. 2 . Next, the slope (m), intercept (b), and standard deviation (σ) were iterated in order to find the minimum error in the simultaneous fit of the linear relationship between the screening test measured values (Fig. 3) and the LRGC/LRMS values along with the FP and FN values. The fitted theoretical lines and measured data are summarized in Fig. 2 . Table 1 gives the values of m and b computed from a standard linear regression, along with the values found to minimize the overall error, including the linear regression as well as FP and FN. The values in parenthesis are the standard errors for the linear regression alone, and it is seen that in all cases the globally fitted values are within a 2 standard error of the linear-regression values.
Screening cutoff
FP and FN for a screening test must be evaluated at the cutoff level at which the test is used. Except for the special case that a test is able to perfectly separate the positive from the negative samples, the choice of a cutoff level requires a trade-off between the two kinds of errors (FP and FN) . Several methods for choosing the cutoff levels have been proposed. There is an intuitive appeal to the cutoff corresponding to the intersection of the FP and FN curves (see Fig. 2 ). This point corresponds to a popular metric, the Youden index. [19] [20] [21] [22] In cases where false-positive and false-negative errors are weighted identically, the Youden index directly gives the optimum cutoff. In cases where they are weighted differently, a modified Youden index can be used to find the optimal cutoffs once the relative weights, or costs, are assigned. In practice, assigning such costs is very difficult.
In the case of screening oil for PCBs, it seems to be clear that a false negative (allowing contaminated oil to be disposed of as uncontaminated) is worse than a false positive (testing uncontaminated oil using the confirmatory test), but attempts to quantify this quickly become arbitrary and subjective. Essentially, the cost of a false positive is monetary (extra testing), while the cost of a false negative is a risk to the ecosystem, and possibly to human health. Quantifying the trade-off between these is both difficult and arbitrary. The European Union offers guidance on cutoff determination 23 (CCα their decision limit is the recommended cutoff), but this limit is inherently weighted towards false-positive errors, 24 devaluing false-negative errors.
In some cases, 14, 25 regulators specify a false-negative rate (<1% for the references given) as a criteria that screening tests must meet. The specific level chosen (1% is common) is arbitrary, but may seem to be more intuitive than the equally arbitrary direct weighting of the errors themselves. Even if a FN (or a FP) is specified, several interpretations are still possible in terms of selecting a cutoff. For example, the worst possible case for false negatives is that all positive samples are just barely above the MRL. In this case, achieving a 1% FN suggests selecting a cutoff equal to the MRL minus 2.4 standard deviations. This very conservative approach should catch well over 99% of positive samples in any real sample distribution, but it does so at the expense of additional FP decreasing the utility of the screening program overall.
As noted above, and quantified in Eqs. (5) and (6), the performance of the screening tests will strongly depend on the actual distribution of samples in the population to be screened. This distribution is not generally known, but tests can be, and sometimes have been validated using real samples taken from the actual population. 26 
Calculation of screening utility
Japanese regulators began with a requirement that the FN must be less than 1%, and moved from that to specifying a cutoff limit of 0.3. 27 The intent is believed to have been to set a very conservative cutoff. It was also decided to require 2% of the samples that tested negative in the screening to be retested using the confirmatory test. 27 Detailed knowledge of the Japanese transformer oil contamination levels is not available; however, the Japanese government has published some general information. 28 This information gave the value of the occurrence ratio (OR), 33%. Figure 4 shows the numbers published in their study, along with a 4 parameter function fitted to the published data. Some fitted function is necessary because the resolution of the data bins needs to match, or exceed, the resolution of the screening method (0.1 ppm) in order to make a meaningful simulation.
The only remaining parameter needed to apply Eq. (2) to estimate cost savings is the cost ratio (CR) of the confirmatory test relative to the screening test. Hard numbers are difficult to come by for these, because the prices of the tests are subject to negotiation, especially where large numbers of tests are needed, as is the case in transformer oil testing. Regarding the cost estimates given in Table 2 , a CR of 2 was chosen for both commercial tests.
As come in Table 2 , even at a modest cost ratio of 2, savings are possible using the screening tests (waste of time is not considered). Possibly of greater interest than the specific prediction is how the cost savings vary with different OR or FP rates. Figures 5A and 5B show the case of a varied parameter (OR and FP) simulation result (FN was used from Table 2 as fixed values). A low OR and a low FP give higher savings, but 
Conclusions
Implementing a screening program in regulatory testing is not guaranteed to reduce the costs. Testers should carefully consider the sample population to be screened, the regulatory requirements, and the performance and cost of available screening tests before deciding to implement a screening program. The approach described in this paper offers a way to estimate a screening test's performance (in terms of FP and FN) from a limited set of test samples, and an estimate of the sample population. In combination with a simple cost model, testers can make reasonable estimates about the potential for cost savings. PCB screening was used as an example system, but the developed model is expected to be useful for other screening analysis. Table 2 . Panel B gives the screening savings increase as the FP rate decreases. For Panel B, the OR, FN, and FT values are set to those given for SCAS in Table 2 . 
